Skip to main content

Table 2 Validation of pathway predictions

From: A genomic analysis of mouse models of breast cancer reveals molecular features ofmouse models and relationships to human breast cancer

Model Pathway Effect References
APC cKO B-Catenin Demonstrated high activation of β-catenin signaling in thesetumors. [65]
APC cKO Myc High levels of Myc demonstrated by IHC in these mammary tumors. [65]
BRCA & P53 mut EGFR Using IHC, EGFR was shown to be overexpressed in this mouse model. [68]
DMBA Ras Observation of H-Ras mutations in mammary hyperplastic outgrowthsafter treatment with DMBA. [69]
DMBA EGFR Using western blot and IHC, EGFR signaling was shown to be active inDMBA induced mammary tumors. [70]
ETV6-Ntrk3 Src ETV6-Ntrk3 binds to and activates c-Src, and inhibition of c-Srcactivation blocks EN transforming activity using mouse engineeredmouse embryonic fibroblasts. [71]
Myc Ras Activating mutations in K-Ras found in a subset MMTV-Myc inducedtumors with a predicted elevation of Ras signalling. [15]
Myc B-Catenin IHC analysis demonstrates higher expression of B-Catenin in themicroacinar histology of Myc driven tumors. [15]
Myc E2F1 E2F2 E2F3 E2F loss altered tumor latency and Myc proliferative effects on themammary gland. [20]
Neu Akt Akt loss effects tumor development in the MMTV-Neu mouse model. [72]
Neu B-Catenin Using a beta-gal reporter, ß-catenin/TCF-dependent transcriptionwas shown to be elevated in MMTV-Neu mouse mammary glands. [73]
Notch B-Catenin Knocking down Notch in a human breast cancer cell line also impactedlevels of beta-catenin. [74]
PyMT Tgfb Blockade of TGF-beta inhibits mammary tumor metastasis. [75]
PyMT Src Loss of c-Src greatly reduced the occurrence of mammary tumors in theMMTV-PyMT mouse model. [76]
Tag Ras K-ras amplifications observed in large t-antigen mediatedtumorigeneis. [77]
Tag E2F2 E2F3 RB KO Large T Antigen simulates loss of Rb by leading to deregulatedacitvation of the E2F transcription factors. [78]
Wnt p53 MMTV-Wnt1 mammary tumors with mutant p53 exhibited a superior clinicalresponse compared to tumors with wild-type p53. [79]
  1. DMBA, 7,12-dimethylbenz[a]anthracene; EGFR, epidermal growth factorreceptor; IHC, immunohistochemistry; MMTV, mouse mammary tumor virus; PyMT,polyoma middle T; TGF, transforming growth factor.